ASTRAZENECA PLC

EMA recommends AstraZeneca’s Datroway for metastatic triple‑negative breast cancer, boosting investor confidence and positioning it as the first TROP2‑directed therapy in Europe.

FDA approves AstraZeneca’s Truqap for PTEN‑deficient prostate cancer, marking the first targeted therapy for this rare subtype while priority review is granted to Ultomiris for IgA nephropathy, boosting AstraZeneca’s oncology and rare‑disease portfo…

Discover how AstraZeneca’s recent FDA approval of Imfinzi for bladder cancer and targeted anselamimab results reshape its oncology strategy and market outlook.

Explore how AstraZeneca’s May 2026 FDA approvals of BAXFENDY™ and Enhertu shape its market and oncology pipeline—and why shares slipped.

Discover AstraZeneca’s AI partnership with Owkin, breakthrough hypoparathyroidism drug results, and recent patent moves – all shaping the future of pharma.

Discover why Deutsche Bank upgraded AstraZeneca’s target to 11,500 GBp: a strong oncology pipeline, solid balance sheet and steady growth outlook make AZN a top pharma pick for investors.

Discover how AstraZeneca’s new U.S. biopharma leadership and Nasdaq‑100 exit sharpen growth focus and boost shareholder value.

Explore AstraZeneca’s latest oncology news: LATIFY setback, BTD for ENHERTU, and a KRAS partnership—what this means for investors and the future of cancer therapy.

Explore how AstraZeneca’s EU Saphnelo approval and U.S. Enhertu launch drive growth—while a pending vaccine lawsuit adds new risk to investor outlook.

Read how AstraZeneca beat Q3 earnings expectations, driven by oncology & cardiovascular sales, with a strong pipeline and U.S. pricing deal boosting confidence for 2026.